FIGO 2023 Upstaging: Overtreatment or Overdue Precision?
Sep 1, 2026 - 31:57
Radio and PodcastLive Radio & Podcasts
Science & Medicine
Understanding the Implications of the Platinum-Free Interval in Endometrial Cancer
Editor’s Choice: Platinum-free interval and response to platinum retreatment or lenvatinib/pembrolizumab in patients with recurrent endometrial cancer: A real-world endometrial cancer molecularly targeted therapy consort...
Related Episodes
Continue listening to more episodes from Gynecologic Oncology.
ERAS 2026: Key Updates Every Gynecologic Oncologist Should Know
Jul 31, 2026 - 26:32
Beyond the Binary: Unpacking Molecular Diversity in PMMR Endometrial Cancer
Jul 29, 2026 - 25:53
PARP Inhibitors in Ovarian Cancer: A Society of Gynecologic Oncology Podcast
May 8, 2026 - 19:50
Home the Same Day? Testing the Limits in Ovarian Cancer Debulking Surgery
Apr 8, 2026 - 18:21
Recognizing and Managing ADC-Associated Pulmonary Toxicities
Mar 16, 2026 - 29:40
In good SHAPE
Feb 1, 2026 - 23:45